Recent reports suggest that molecular therapies targeting ANGPTL3 and its encoded protein angiopoietin-like protein 3 have clinical potential comparable to therapies targeting PCSK9 and its encoded protein proprotein convertase subtilisin/kexin type 9. By mainly affecting triglyceride-rich lipoproteins, ANGPTL3 inhibition might prove complementary to LDL cholesterol lowering with PCSK9 blockade.

中文翻译：

---

心血管内分泌学：ANGPTL3是下一个PCSK9吗？

最近的报道表明，靶向ANGPTL3及其编码的蛋白血管生成素样蛋白3的分子疗法具有与靶向PCSK9及其编码的蛋白原蛋白转化酶枯草杆菌蛋白酶/ kexin 9型疗法相当的临床潜力。通过主要影响富含甘油三酸酯的脂蛋白，ANGPTL3抑制作用可能证明是相辅相成的通过PCSK9阻滞降低LDL胆固醇。